lipid‐lowering

Lipid-lowering agent-1 is a potent lipid-lowering compound that significantly inhibits the pharmacological effects of low-density lipoprotein cholesterol (LDLC) and promotes high-density lipoprotein cholesterol (HDLC) production. In rats on a high-fat diet, it substantially reduces fat.

Lipid-lowering agent-2 (Compound 14d) exhibits oral efficacy as a lipid-lowering agent with an EC50 of 0.06 μM. It works by inhibiting lipid synthesis and activating the AMPK signaling pathway, contributing to its anti-obesity effects. Additionally, Lipid-lowering agent-2 suppresses food intake in mice, enhances glucose metabolism, and reduces body weight and adipose tissue in mice induced by a high-fat diet (HFD).

Mevastatin (ML236B) is an HMG-CoA reductase inhibitor that was initially isolated from the mold Pythium ultimum. Mevastatin was the first statin to enter clinical trials.

AZ-1355 is a novel dibenzoxepine derivative with lipid-lowering properties.

Cerivastatin is an orally active and highly effective HMG-CoA reductase inhibitor with anticancer and lipid-lowering effects. Cerivastatin can reduce low-density lipoprotein cholesterol levels, inhibit the proliferation and invasion of MDA-MB-231 cells, and can be used to study primary hyperlipidemia.

Ragaglitazar(NNC-61-0029) is a potent dual activator of PPARγ and PPARα, which shows improved insulin sensitization and lipid-lowering potential in animal models and can be used to study type 2 diabetes.

Sultosilic acid piperazine salt (A-585) is a novel lipid-lowering compound that can be used to study type IIb familial combined hyperlipidemia.

Beclobrate (Sgd 24774) is a novel orally available fibric acid derivative that has shown significant lipid and cholesterol-lowering activity in rodents and may be used in the study of primary hyperlipoproteinemia.

Dihydrocaffeic acid is a metabolite of chlorogenic acid, a well-known antioxidant component with antioxidant, anti-Alzheimer's disease, neuroprotective, arousal and lipid-lowering effects.

Naringin (Naringoside), a flavanone glycoside, exerts various of pharmacological effects such as blood lipid lowering, antioxidant activity, anticancer activity, and inhibition of cytochrome P450 enzymes.

Hesperidin (Cirantin) is a flavanone glycoside found in citrus fruits with antioxidant, anti-inflammatory, anti-carcinogenic, and antihypertensive and lipid-lowering activity.

Lovastatin (MK-803) is an HMG-CoA reductase inhibitor (IC50=3.4 nM). Lovastatin lowers cholesterol and is commonly used as a lipid-lowering agent in the treatment of hypercholesterolemia.

Methyl-β-cyclodextrin (Methyl-beta-cyclodextrin) is a macrocyclic compound utilized as a solubilizer for hydrophobic substances in biological studies, and serves as a lipid raft inhibitor with cholesterol-lowering and potential antitumor activities.

Anagliptin (SK-0403) is a potent inhibitor of DPP-4 (IC50 of 3.8 nM) used in the treatment of type 2 diabetes mellitus.

Cerivastatin sodium (BAY W 6228 sodium) is an orally active and highly potent HMG-CoA reductase inhibitor with lipid-lowering activity that can reduce low-density lipoprotein cholesterol levels. Cerivastatin sodium has anticancer effects and can be used to study primary hyperlipidemia.

GW 7647 is an effective and highly selective PPARα agonist, the EC 50 values of human PPARα, PPARγ and PPARδ receptors are 6,1100 and 6200 nM, respectively. GW 7647 can reduce the production of nitric oxide in macrophages and has lipid-lowering and anti-inflammatory properties in the body.

1. Eriocitrin (Eriodictyol-7-O-Rutinoside) is powerful antioxidative flavonoid; (1) Prevents oxidative damages caused by acute exercise-induced oxidative stress.(2) Lipid-lowering effects in a rat model of high-fat diet. 2. Dietary Eriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis. 3. Eriocitrin and Apigenin were identified as new potent inhibitors of human carbonic anhydrase VA isozyme.

CUDA is an effective soluble cyclohydrolase inhibitor with IC50 of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA selectively increases the activity of peroxisome proliferator-activated receptor (PPAR) alpha. CUDA may be valuable for the study of cardiovascular diseases.

IMM-H007 is a novel lipid-lowering agent, increasing abca1 protein expression

6-Raloxifene-β-D-glucopyranoside is a benzothiophene glucuronidated at the 6' position. It is a selective and orally active estrogen receptor antagonist. 6-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss, resorption, and lowering lipid

PPAR agonist 1 is a dual PPAR α γ agonist used for lowering blood glucose, lipid levels, cholesterol, and body weight.

Gemcabene calcium , a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) andexerting anti-inflammatory activity, lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP).

Gemcabene (PD-72953) is a lipid-lowering agent with anti-inflammatory activity. Gemcabene lowers low-density lipoprotein cholesterol and triglycerides, raises high-density lipoprotein cholesterol, and decreases pro-inflammatory acute-phase protein, C-reactive protei

RP 54275 is a naturally occurring fatty acid derivative, a new cholesterol-lowering compound. It activates the peroxisome proliferator-activated receptor gamma (PPARγ) pathway, which is involved in the regulation of lipid metabolism, inflammation and cellular differentiation.